AUTHOR=Zhao Long , Qi Lijuan , Fu Jinhua , Bi Shuqin , Li Lin , Fu Yinghui 

TITLE=Efficacy of Intrauterine Perfusion of Cyclosporin A for Intractable Recurrent Spontaneous Abortion Patients With Endometrial Alloimmune Disorders: A Randomized Controlled Trial

JOURNAL=Frontiers in Physiology

VOLUME=12

YEAR=2021

URL=https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2021.737878

DOI=10.3389/fphys.2021.737878

ISSN=1664-042X

ABSTRACT=<sec><title>Objective</title><p>To explore the therapeutic efficacy of intrauterine perfusion of cyclosporin A (CsA) in intractable recurrent spontaneous abortion (RSA) patients with endometrial alloimmune dysfunction.</p></sec><sec><title>Methods</title><p>This is a randomized controlled trial (RCT) of patients with intractable RSA with endometrial alloimmune disorders. A total of 201 women were enrolled, all of whom had at least 3 serial abortions and endometrial alloimmune dysfunction. Participants were randomly assigned to two groups. The CsA group (<italic>n</italic> = 101) received intrauterine infusion of 250 mg CsA on the 3rd and 7th days after menstruation for 2 menstrual cycles, while the placebo group (<italic>n</italic> = 100) received placebo. The birth of healthy, deformity-free babies was the main study outcome.</p></sec><sec><title>Results</title><p>In total, 75 (74.26%) women in the CsA group and 59 (59.00%) women in the placebo group gave birth to healthy babies [<italic>P</italic> = 0.01, <italic>OR</italic> = 2.01; 95% <italic>CI</italic> (1.10∼3.65)]. Compared to the placebo group, the CsA group had dramatically lower endometrial CD56<sup>+</sup> cell and CD57<sup>+</sup> cell concentrations at the luteal phase of the second menstrual cycle (<italic>P</italic> &lt; 0.05).</p></sec><sec><title>Conclusion</title><p>Intrauterine perfusion of CsA was confirmed to be a promising approach for the treatment of intractable alloimmune RSA.</p></sec>